Back to News
Market Impact: 0.25
InMed Pharmaceuticals Inc. Announces Name Change, Share Consolidation and Shareholder Approval of Mentari Merger
Source: Nasdaq
M&A & RestructuringManagement & Governance
At its November 4, 2026 annual general and special meeting, shareholders of InMed Pharmaceuticals Inc. (now Mentari Therapeutics, Inc.) approved all proposals related to its merger with Mentari Therapeutics, Inc. The provided article text is truncated and gives no further details on the approved items or merger terms.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
INM0.70
More News
- Shield AI To Hit $28.8 Billion Value With $5.3 Billion Radar Acquisition
- Five9 falls 22% on disappointing fourth quarter EPS outlook
- Cloudflare’s appeal won’t fix what’s broken in Delaware’s Chancery Court
- Paraguay President Pena resigns in wake of bank collapse
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Here's where we stand on Kimberly-Clark shares after a better-than-feared quarter